Skip to main content

Table 2 Toxicitiesa

From: Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study

 

UCB n (%)

TCG n (%)

Grade 1–2

Grade 3–4

Grade 1–2

Grade 3–4

Hematological Toxicity

 Trombocytopenia

2 (8)

23 (92)

1 (4.1)

23 (95.8)

 Neutropenia

10 (40)

15 (60)

16 (66.7)

8 (33.3)

 Neutropenic fever

2 (8)

1 (4)

5 (20.8)

2 (8.3)

 Anemia

19 (76)

6 (24)

20 (83.3)

3 (12.5)

Non Hematological Toxicity

 Hepatobiliary disorders

0

1 (4)

2 (8.3)

0

 Mucositis

5 (20)

0

4 (16.7)

0

 Skin disorders

2 (8)

0

1 (4.1)

0

 Cardiac disorders

3 (12)

0

4 (16.7)

0

 Sepsis

2 (8)

0

3 (12.5)

0

 aGVHD

0

1 (4)

0

0

  1. Abbreviations: aGVHD Acute graft versus host disease
  2. aThe severity of adverse events was graded on a scale of 1–5 according to the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0